Abstract:Objective: Drug-induced liver injury (DILI) is a major failure mode in pharmaceutical development. This study aims to address the limitations of existing preclinical models by introducing a high-throughput, microfluidic liver-on-a-chip system, termed as "Curio Barrier Liver Chips," seeded with human liver organoids to enable metabolic and phenotypic morphologic characterization. Methods: Curio Barrier liver chips, fabricated in an 8x2 well configuration, were utilized to establish 3D liver organoid cultures. Human-induced pluripotent stem cells (iPSCs) were differentiated into hepatic-like organoids (HLOs), and their viability, liver-specific functions, and pharmacological responses were assessed over 28 days. Results: The Curiochips successfully maintained liver physiology and function, showing strong albumin secretion and cytochrome P450 (CYP) activities through 28 days. Unlike traditional models requiring millimolar drug concentrations to detect hepatotoxicity, this platform showed increased sensitivity for APAP and FIAU at micromolar concentrations. In situ differentiation of foregut spheroids to liver organoids was also achieved, further simplifying the establishment of liver chips. Furthermore, the chips demonstrated viability, function and DILI responsiveness for 28 days making this an improved model for studying idiosyncratic DILI with prolonged drug exposure and high-throughput capabilities compared to other available systems or primary human hepatocytes. Conclusions: The Curiochips offer an advanced, miniaturized in vitro model for early-stage drug development and a sensitive, responsive and cost-effective means to detect direct hepatotoxicity. The high-throughput capability, coupled with robust functionality and pharmacological responses make it a promising tool for improving the prediction and understanding of DILI mechanisms in general and those that required prolonged drug exposure. The model also opens new avenues for research in other chronic liver diseases. Keywords: Drug-induced liver injury, hepatotoxicity, microfluidic liver chips, microphysiologic liver model, high-throughput screening, iPSC-derived hepatic-like organoids, chronic DILI model, Curiochips.

Liver-on-chips for drug discovery and development

Synergistic Modulation of a Tunable Microenvironment to Fabricate a Liver Fibrosis Chip for Drug Testing.

Construction of in vitro liver-on-a-chip models and application progress

Experimental liver models: From cell culture techniques to microfluidic organs‐on‐chip

State-of-the-art advancements in Liver-on-a-chip (LOC): Integrated biosensors for LOC.

Engineered Liver-on-a-Chip Platform to Mimic Liver Functions and Its Biomedical Applications: A Review

Liver Spheroids on Chips as Emerging Platforms for Drug Screening

DigiLoCS: A Leap Forward in Predictive Organ-on-Chip Simulations

Development of novel tools for the in vitro investigation of drug-induced liver injury

Organ-on-Chip Devices towards Applications in Drug Development and Screening: A Review

Organ-on-Chip Devices Toward Applications in Drug Development and Screening

Liver-on-a-Chip Integrated with Label-Free Optical Biosensors for Rapid and Continuous Monitoring of Drug-Induced Toxicity

Hydrogel Microfluidic‐based Liver‐on‐a‐chip: Mimicking the Mass Transfer and Structural Features of Liver

In vitro and in silico liver models: Current trends, challenges and opportunities

A High-Throughput Microphysiological Liver Chip System to Model Direct and Idiosyncratic Drug-Induced Liver Injury Using Human Liver Organoids

Human Hepatobiliary Organoids: Recent Advances in Drug Toxicity Verification and Drug Screening

Liver organoid as a 3D in vitro model for drug validation and toxicity assessment

Engineering Organoids-on-chips for Drug Testing and Evaluation

Beyond the hype and toward application: liver complex in vitro models in preclinical drug safety

Advanced Liver-on-a-Chip Model for Evaluating Drug Metabolism and Hepatotoxicity

Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology